Cancer Stem Cell News Volume 2.35 | Sep 4 2013

Cancer Stem Cell News 2.35 September 4, 2013

Cancer Stem Cell News

     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter

Brain Tumor Initiating Cells Adapt to Restricted Nutrition through Preferential Glucose Uptake
Researchers report that nutrient restriction contributes to tumor progression by enriching for brain tumor initiating cells (BTICs) owing to preferential BTIC survival and to adaptation of non-BTICs through acquisition of BTIC features. [Nat Neurosci] Abstract
[Free On-Demand Webinar] Detect Cancer Stem Cells with ALDEFLUOR™ - Watch Now.

PUBLICATIONS (Ranked by impact factor of the journal)
Triple Negative Breast Cancer Initiating Cell Subsets Differ in Functional and Molecular Characteristics and in γ-Secretase Inhibitor Drug Responses
Breast tumor-initiating stem cells (T-ISCs) are known to be enriched in CD44+CD24neg/low cells. Investigators identified two T-ISC subsets within this population in triple negative breast cancer lines and dissociated primary breast cancer cultures: CD44+CD24low+ subpopulation generates CD44+CD24neg progeny with reduced sphere formation and tumorigenicity. [EMBO Mol Med] Full Article

p27kip1 Maintains a Subset of Leukemia Stem Cells in the Quiescent State in Murine MLL-Leukemia
p27 deletion significantly compromises the leukemogenic capacity of CD117+CD11blo MLL-AF9-leukemic cells (LCs) by reducing the frequency of leukemic stem cells but does not do so in HOXA9/MEIS1-LCs [Mol Oncol] [Mol Oncol] Abstract

Radiation-Induced Notch Signaling in Breast Cancer Stem Cells
Scientists showed that Notch receptor and ligand expression during the first 48 hours after irradiation followed a complex radiation dose-dependent pattern and was most pronounced in mammospheres, enriched for breast cancer stem cells. [Int J Radiat Oncol Biol Phys] Abstract

Alteration of Cancer Stem Cell-Like Phenotype by Histone Deacetylase Inhibitors in Squamous Cell Carcinoma of the Head and Neck
The authors investigated the effects of two histone deacetylase inhibitors, suberoylanilide hydroxamic acid and trichostatin A, on two CD44+ cancer stem-like cell lines from SCCHN cultured in serum-free medium containing epidermal growth factor and basic fibroblast growth factor. [Cancer Sci] Abstract

Expansion of CD133-Positive Glioma Cells in Recurrent De Novo Glioblastomas after Radiotherapy and Chemotherapy Laboratory Investigation
Recent evidence suggests that a glioma stem cell subpopulation may determine the biological behavior of tumors, including resistance to therapy. To investigate this hypothesis, the authors examined varying grades of gliomas for stem cell marker expressions and histopathological changes between primary and recurrent tumors. [J Neurosurg] Abstract

Clinical Significances and Prognostic Value of Cancer Stem-Like Cells Markers and Vasculogenic Mimicry in Renal Cell Carcinoma
Scientists investigated the clinical significances and prognostic value of CD133 and CD44 (markers of cancer stem-like cells), and vasculogenic mimicry in renal cell carcinoma. [J Surg Oncol] Abstract

Effects of Ellipticine on ALDH1A1-Expressing Breast Cancer Stem Cells-An In Vitro and In Silico Study
Investigators examined the plant alkaloid ellipticine for its efficacy to inhibit the expression of aldehyde dehydrogenase 1 class A1 (ALDH1A1)-positive breast cancer stem cells by in vitro and in silico methods. [Tumor Biol] Abstract

Expression of Cancer Stem Cell Markers Is More Frequent in Anaplastic Thyroid Carcinoma Compared to Papillary Thyroid Carcinoma and Is Related to Adverse Clinical Outcome
Researchers explored the expression of various cancer stem cell markers in thyroid carcinoma tissues and analyzed their clinical significance. [J Clin Pathol] Abstract

Implication of Tumor Stem-Like Cells in the Tumorigenesis of Sporadic Paraganglioma
Researchers found a subgroup of human paraganglioma from ten clinical samples displayed definitive markers of CD133 and/or nestin, the fundamental features of neural stem cells capable of self-renewal and differentiation. [Med Oncol] Abstract

Identification of FDA-Approved Drugs Targeting Breast Cancer Stem Cells along with Biomarkers of Sensitivity
Gene expression datasets of cancer stem cells (CSCs) from six studies were subjected to connectivity map to identify drugs that may ameliorate gene expression patterns unique to CSCs. All-trans retinoic acid was negatively connected with gene expression in CSCs. [Sci Rep] Full Article

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.

Therapy Targets in Glioblastoma and Cancer Stem Cells: Lessons from Hematopoietic Neoplasms
The authors focus on a putative novel therapy targets represented by markers described to define cancer stem/initiating cells in malignant gliomas, which have been called ‘leukemia of the brain’, given their rapid migration and evolution. [J Cell Mol Med] Full Article

Breast Cancer Adaptive Resistance: HER2 and Cancer Stem Cell Repopulation in a Heterogeneous Tumor Society
The authors discuss the cancer stem cell-mediated tumor repopulation in acquired resistance of breast cancer in this review. [J Cancer Res Clin Oncol] Full Article

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Stem Cell Agency Awards More than $40 Million in New Research Grants
The California Institute for Regenerative Medicine’s governing board, the Independent Citizens Oversight Committee, approved $40 million in funding for researchers at 10 institutions including Stanford, UCLA, UC San Diego, Human BioMolecular Research Institute, Cedars-Sinai Medical Center, The Gladstone Institutes, Sanford-Burnham Medical Research Institute, The Salk Institute, Numerate, Inc. and UC Irvine as part of its Early Translational IV Research awards. [California Institute for Regenerative Medicine] Press Release

Four UCLA Researchers Receive CIRM Early Translational Grants
Four prominent researchers from UCLA’s Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research have received Early Translational research awards totaling approximately $13 million from the California Institute for Regenerative Medicine (CIRM), the state stem cell agency. [University of California, Los Angeles] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Stem Cell Congress 2013
November 4-5th, 2013
London, United Kingdom

Visit our events page to see a complete list of events in the cancer stem cell community.

NEW Assistant Professor – Developmental and Stem Cell Biology (METU Department of Biology)

Principal Scientist – Cancer Stem Cells (Pharma Professionals Europe Ltd)

Postdoctoral Fellowships – Cancer Stem Cell Biology and Pharmacogenomics (Biotech Research & Innovation Center, University of Copenhagen)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Postdoctoral Appointee – Cell Cycle Regulation in Tumor Stem Cells (Rutgers University, Rutgers Cancer Institute of New Jersey)

Research Technician – Self-Renewal of Cancer Stem Cells (University of Chicago)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or Suggestions? Email with your feedback.

Learn more about Cancer Stem Cell News: Archives | Events | Contact Us